Skip to content
← Full study record

NCT00471497 · ADVERSE EVENTS

Adverse events

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) · Source last updated 2020-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Adverse Event (AE) time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 28 days post treatment, up to maximum duration of approx. 11 years.
Other-event reporting threshold
5%

Adverse Event (AE): Any sign or symptom that occurs during the study treatment plus 28 days post treatment.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Imatinib 400 mg QD

Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated

96 / 280275 / 2804 / 280
Nilotinib 300 mg BID

Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.

112 / 279276 / 27910 / 279
Nilotinib 400 mg BID

Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.

126 / 277272 / 2775 / 277
All Patients

All patients randomized in the study to all 3 arms and received at least one dose of study drug.

334 / 836823 / 83619 / 836

Group identifiers: EG000: Imatinib 400 mg QD · EG001: Nilotinib 300 mg BID · EG002: Nilotinib 400 mg BID · EG003: All Patients

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      11
      num At Risk
      836
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Anaemia macrocytic
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      2
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      3
      num At Risk
      836
    term
    Febrile neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Hypoplastic anaemia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      2
      num At Risk
      836
    term
    Iron deficiency anaemia
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Leukocytosis
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      3
      num At Risk
      836
    term
    Leukopenia
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      9
      num At Risk
      836
    term
    Neutropenia
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      2
      num At Risk
      836
    term
    Pancytopenia
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      5
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      13
      num At Risk
      836
    term
    Thrombocytopenia
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Acute coronary syndrome
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      7
      num At Risk
      836
    term
    Acute myocardial infarction

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      71
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      38
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      45
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      154
      num At Risk
      836
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      47
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      23
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      22
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      92
      num At Risk
      836
    term
    Leukopenia
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      59
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      45
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      30
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      134
      num At Risk
      836
    term
    Neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      56
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      54
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      58
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      168
      num At Risk
      836
    term
    Thrombocytopenia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      3
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      14
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      10
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      27
      num At Risk
      836
    term
    Angina pectoris
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      12
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      19
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      19
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      50
      num At Risk
      836
    term
    Palpitations
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Ear and labyrinth disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      12
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      13
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      14
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      39
      num At Risk
      836
    term
    Vertigo
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      26
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      34
      num At Risk
      836
    term
    Conjunctival haemorrhage
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      20
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      20
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      21
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      61
      num At Risk
      836
    term
    Dry eye
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      44
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      52
      num At Risk
      836
    term
    Eyelid oedema
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      45
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      50
      num At Risk
      836
    term
    Periorbital oedema
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      13
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      12
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      15
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      40
      num At Risk
      836
    term
    Abdominal distension
Complete source fields
description
Adverse Event (AE): Any sign or symptom that occurs during the study treatment plus 28 days post treatment.
event Groups
  1. deaths Num Affected
    4
    deaths Num At Risk
    280
    description
    Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated
    id
    EG000
    other Num Affected
    275
    other Num At Risk
    280
    serious Num Affected
    96
    serious Num At Risk
    280
    title
    Imatinib 400 mg QD
  2. deaths Num Affected
    10
    deaths Num At Risk
    279
    description
    Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.
    id
    EG001
    other Num Affected
    276
    other Num At Risk
    279
    serious Num Affected
    112
    serious Num At Risk
    279
    title
    Nilotinib 300 mg BID
  3. deaths Num Affected
    5
    deaths Num At Risk
    277
    description
    Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.
    id
    EG002
    other Num Affected
    272
    other Num At Risk
    277
    serious Num Affected
    126
    serious Num At Risk
    277
    title
    Nilotinib 400 mg BID
  4. deaths Num Affected
    19
    deaths Num At Risk
    836
    description
    All patients randomized in the study to all 3 arms and received at least one dose of study drug.
    id
    EG003
    other Num Affected
    823
    other Num At Risk
    836
    serious Num Affected
    334
    serious Num At Risk
    836
    title
    All Patients
frequency Threshold
5
other Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      71
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      38
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      45
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      154
      num At Risk
      836
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      47
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      23
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      22
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      92
      num At Risk
      836
    term
    Leukopenia
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      59
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      45
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      30
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      134
      num At Risk
      836
    term
    Neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      56
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      54
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      58
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      168
      num At Risk
      836
    term
    Thrombocytopenia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      3
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      14
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      10
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      27
      num At Risk
      836
    term
    Angina pectoris
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      12
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      19
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      19
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      50
      num At Risk
      836
    term
    Palpitations
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Ear and labyrinth disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      12
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      13
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      14
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      39
      num At Risk
      836
    term
    Vertigo
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      26
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      34
      num At Risk
      836
    term
    Conjunctival haemorrhage
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      20
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      20
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      21
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      61
      num At Risk
      836
    term
    Dry eye
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      44
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      52
      num At Risk
      836
    term
    Eyelid oedema
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      45
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      50
      num At Risk
      836
    term
    Periorbital oedema
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      13
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      12
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      15
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      40
      num At Risk
      836
    term
    Abdominal distension
serious Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      11
      num At Risk
      836
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Anaemia macrocytic
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      2
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      3
      num At Risk
      836
    term
    Febrile neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Hypoplastic anaemia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      2
      num At Risk
      836
    term
    Iron deficiency anaemia
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Leukocytosis
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      3
      num At Risk
      836
    term
    Leukopenia
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      9
      num At Risk
      836
    term
    Neutropenia
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      2
      num At Risk
      836
    term
    Pancytopenia
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      5
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      13
      num At Risk
      836
    term
    Thrombocytopenia
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      1
      num At Risk
      836
    term
    Acute coronary syndrome
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA (22.0)
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      280
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      279
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      277
    4. group Id
      EG003
      num Affected
      7
      num At Risk
      836
    term
    Acute myocardial infarction
time Frame
Adverse Event (AE) time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 28 days post treatment, up to maximum duration of approx. 11 years.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice